| Item Type | Name |
|
Concept
|
Antineoplastic Combined Chemotherapy Protocols
|
|
Concept
|
Drug Therapy, Combination
|
|
Concept
|
Chemotherapy, Adjuvant
|
|
Concept
|
Maintenance Chemotherapy
|
|
Academic Article
|
Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.
|
|
Academic Article
|
Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer.
|
|
Academic Article
|
Paclitaxel and carboplatin in early phase studies: Roswell Park Cancer Institute experience in the subset of patients with lung cancer.
|
|
Academic Article
|
The clinical development of paclitaxel and the paclitaxel/carboplatin combination.
|
|
Academic Article
|
Metastatic colorectal cancer.
|
|
Academic Article
|
Malignant pleural mesothelioma.
|
|
Academic Article
|
Pemetrexed in pancreatic cancer.
|
|
Academic Article
|
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
|
|
Academic Article
|
Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
|
|
Academic Article
|
Pemetrexed in patients with gastrointestinal carcinoma.
|
|
Academic Article
|
The pemetrexed/gemcitabine combination in pancreatic cancer.
|
|
Academic Article
|
Oral fluoropyrimidine treatment of colorectal cancer.
|
|
Academic Article
|
Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma.
|
|
Academic Article
|
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.
|
|
Academic Article
|
In focus: advanced pancreatic cancer.
|
|
Academic Article
|
Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancer.
|
|
Academic Article
|
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer.
|
|
Academic Article
|
Pancreatic cancer: an update.
|
|
Academic Article
|
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.
|
|
Academic Article
|
Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
|
|
Academic Article
|
A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer.
|
|
Academic Article
|
Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma.
|
|
Academic Article
|
Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.
|
|
Academic Article
|
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.
|
|
Academic Article
|
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
|
|
Academic Article
|
Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium.
|
|
Academic Article
|
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
|
|
Academic Article
|
Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinoma.
|
|
Academic Article
|
Update on malignant pleural mesothelioma.
|
|
Academic Article
|
A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.
|
|
Academic Article
|
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.
|
|
Academic Article
|
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
|
|
Academic Article
|
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).
|
|
Academic Article
|
A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.
|
|
Academic Article
|
High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631.
|
|
Academic Article
|
The role of gemcitabine in the treatment of malignant mesothelioma.
|
|
Academic Article
|
Chemotherapy for advanced pancreatic cancer: past, present, and future.
|
|
Academic Article
|
Front-line therapy of advanced pancreatic cancer.
|
|
Academic Article
|
A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903.
|
|
Academic Article
|
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
|
|
Academic Article
|
Utilisation of a thoracic oncology database to capture radiological and pathological images for evaluation of response to chemotherapy in patients with malignant pleural mesothelioma.
|
|
Academic Article
|
Validity of the FACT Hepatobiliary (FACT-Hep) questionnaire for assessing disease-related symptoms and health-related quality of life in patients with metastatic pancreatic cancer.
|
|
Academic Article
|
Lung volume measurements as a surrogate marker for patient response in malignant pleural mesothelioma.
|
|
Academic Article
|
Peritoneal mesothelioma: the site of origin matters.
|
|
Academic Article
|
Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
|
|
Academic Article
|
Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma.
|
|
Academic Article
|
25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance).
|
|
Academic Article
|
Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors.
|
|
Academic Article
|
Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802).
|
|
Academic Article
|
Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance.
|
|
Academic Article
|
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.
|
|
Academic Article
|
The Vulnerable Elders Survey-13 predicts mortality in older adults with later-stage colorectal cancer receiving chemotherapy: a prospective pilot study.
|
|
Academic Article
|
Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab.
|
|
Academic Article
|
Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance).
|
|
Academic Article
|
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer.
|
|
Academic Article
|
A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma.
|
|
Academic Article
|
208O_PR: CRS-207 with chemotherapy (chemo) in malignant pleural mesothelioma (MPM): Results from a phase 1b trial.
|
|
Academic Article
|
Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma.
|
|
Academic Article
|
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.
|
|
Academic Article
|
A phase 2 clinical trial of pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients with peritoneal mesothelioma (PM).
|
|
Academic Article
|
Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer.
|
|
Academic Article
|
The impact of changes in radiographic sarcopenia on overall survival in older adults undergoing different treatment pathways for pancreatic cancer.
|
|
Academic Article
|
The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation.
|
|
Academic Article
|
Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis: The CALGB 89803/Alliance Trial.
|
|
Academic Article
|
Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study.
|
|
Academic Article
|
Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance).
|
|
Academic Article
|
Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.
|
|
Academic Article
|
A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies.
|
|
Academic Article
|
Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.
|
|
Academic Article
|
Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy.
|
|
Academic Article
|
A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma.
|
|
Academic Article
|
Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study).
|
|
Academic Article
|
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
|
|
Academic Article
|
Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma.
|
|
Academic Article
|
Perioperative Gemcitabine?+?Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial.
|
|
Academic Article
|
Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype-Guided Dosing.
|
|
Academic Article
|
Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation.
|
|
Academic Article
|
Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial.
|
|
Academic Article
|
Olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO trial.
|
|
Academic Article
|
Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901.
|
|
Academic Article
|
Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy.
|
|
Academic Article
|
Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance).
|
|
Academic Article
|
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors.
|
|
Academic Article
|
Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens.
|
|
Academic Article
|
Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.
|
|
Academic Article
|
Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels.
|
|
Academic Article
|
Diet- and Lifestyle-Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance).
|
|
Academic Article
|
Marital Status, Living Arrangement, and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings from CALGB 89803 (Alliance).
|
|
Academic Article
|
ASO Visual Abstract: Phase II Prospective Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy with and without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels.
|
|
Academic Article
|
A population-based evaluation of tunica vaginalis mesothelioma: An analysis of the National Cancer Database.
|
|
Academic Article
|
Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial.
|
|
Academic Article
|
Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma.
|